Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Exclusion Criteria

• •Squamous cell, small cell, or mixed histology.
• •Known history of bleeding diathesis or coagulopathy.
• •Cavitary tumors or tumors abutting large blood vessels.
• •Bleeding: Clinically significant bleeding, such as gross hematuria, GI bleeding and hemoptysis, within 12 months of Screening.
• •Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism) within 6 months of Screening.
• •Ongoing therapy with oral or parenteral anticoagulants.
• •Concurrent estrogens, anti-estrogens or progesterone compounds.
• •Grade 2 or higher peripheral neuropathy.
• •Radiotherapy within 2 weeks preceding Study Day 1.
• •Symptomatic or clinically active brain metastases.
• •Major surgery within 4 weeks of Study Day 1.
• •Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease).
• •Symptomatic coronary artery disease, cerebrovascular accident,transient ischemic attack, myocardial infarction, or unstable angina pectoris within 6 months of Screening.